Asthma and Fungus: Role in Allergic Bronchopulmonary Aspergillosis (ABPA) and Other Conditions
- 114 Downloads
Asthma is an allergic, respiratory disorder characterized by hyper responsiveness of the airway to external stimuli. Considerable research is currently being directed towards understanding the role of environmental and genetic factors contributing to the development of asthma and its severity. Recent years have seen a substantial rise in evidence linking fungi to asthma. Few major clinical conditions associated with fungal sensitization and hypersensitive immune response are Allergic bronchopulmonary aspergillosis (ABPA), Allergic fungal rhinosinusitis (AFRS) and Severe asthma with fungal sensitization (SAFS). The most common fungi implicated in these conditions belong to genus Aspergillus, although an association with several other fungi has been described. In this review authors discuss the varying clinical characteristics of fungus induced respiratory complications in individuals with asthma. They also highlight the epidemiology of these conditions including their prevalence in children and their fungal etiological profile. Laboratory diagnostic methods and clinical case definitions have also been discussed. Future studies evaluating the role of fungal exposure and susceptibility to asthma are required. Till date there are no guidelines for the diagnosis and treatment of ABPA in pediatric population, thus it is also imperative to establish validated clinical definitions of fungal allergic manifestations in pediatric patients with asthma to fully understand this complex interaction.
KeywordsAsthma Fungus Allergic bronchopulmonary aspergillosis (ABPA)
MS: Article conceived and drafted. NP: Literature search and writing; SS and GN: Literature search and review. MS will act as guarantor for this paper.
Compliance with Ethical Standards
Conflict of Interest
Source of Funding
ICMR, New Delhi has supported the fellowship of Ms. Nandini Paul.
- 13.Chetty A, Bhargava S, Jain RK. Allergic bronchopulmonary aspergillosis in Indian children with bronchial asthma. Ann Allergy. 1985;54:46–9.Google Scholar
- 14.Singh M, Das S, Chauhan A, et al. The diagnostic criteria for allergic bronchopulmonary aspergillosis in children with poorly controlled asthma need to be re-evaluated. Acta Pediatr. 2015;105:e206–9.Google Scholar
- 22.Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med. 1986;146:916–8.Google Scholar
- 23.Kumar R. Mild, moderate and severe forms of allergic bronchopulmonary aspergillosis. A clinical and serologic evaluation. Chest. 2003;124:890–2.Google Scholar
- 24.Agarwal R, Khan A, Gupta D, Aggarwal AN, Saxena AK, Chakrabarti A. An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus. PLoS One. 2010;5:1–9.Google Scholar
- 25.Agarwal R. Pictorial essay: allergic bronchopulmonary aspergillosis. World J Radiol. 2011;3:178–81.Google Scholar
- 26.Kumar R. Mild, moderate, and severe forms of allergic bronchopulmonary aspergillosis: a clinical and serologic evaluation. Chest. 2003;124:890–2.Google Scholar
- 34.Kurup VP, Raju R, Manickam P. Profile of gene expression in a murine model of allergic bronchopulmonary aspergillosis. Society. 2005;73:4381–4.Google Scholar
- 42.FDA Safety Notice. FDA issues early communication concerning safety of asthma drug Xolair. MD Consult July 17, 2009.Google Scholar